ArticleChinese medicine2025
Ershen Dan attenuates atherosclerosis by modulating the NOTCH1/NF-κB/NLRP3 signaling pathway to suppress M1 macrophage polarization.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting NF-κB Signaling with Natural Products: A Promising Therapeutic Strategy for Cardiovascular Diseases.Biomolecules · 2026Review
- Regulation of microglial polarization via notch signaling pathway by intrathecal administration of tanshinone IIA-PLGA sustained-release microspheres to promote neurological recovery after spinal cord injury.Frontiers in bioengineering and biotechnology · 2026Article
- Venenum bufonis and its active constituents alleviate RSV-induced pneumonia in mice by suppressing macrophage infiltration and NLRP3 inflammasome activation.Virus research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAtherosclerosis is a chronic inflammatory disease. Inhibition of macrophage inflammatory secretion is the key to the prevention and treatment of atherosclerosis. Ershen Dan (ESD) has been shown to be effective in treating atherosclerosis; however, its pharmacological mechanisms remain unclear. This study elucidated the mechanism of action of ESD by investigating its relationship with macrophages. MATERIALS AND
methodsThe chemical composition of ESD was analyzed using ultra performance liquid chromatography (UPLC)-Q-Exactive-tandem mass spectrometry (MS/MS). In the in vivo experiments, serum levels of low-density lipoprotein (LDL), triglycerides (TG), and total cholesterol (TC) in ApoE
resultsTwenty bioactive chemical components were identified in ESD. In vivo studies demonstrated that ESD inhibits macrophage secretion of inflammatory factors through the NOTCH1/NF-κB/NLRP3 signaling pathway, indicating its therapeutic potential for atherosclerosis. In vitro studies further revealed that ginsenoside Rg
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.